Hypertension Tops 1 Billion Worldwide; Significant Implications for Pharma and Med Device Industries
HUNTINGTON BEACH, Calif., June 18, 2015 /PRNewswire/ — A new analysis from Dymedex Consulting reveals that due to increasing obesity rates, hypertension now affects over one billion people worldwide. This new study is available exclusively from Life Science Intelligence.
Hypertension rates in African countries are reaching critical levels, with some countries in North Africa nearing 50% of the adult population affected by hypertension. The high prevalence rate is growing despite the relatively young average age in most African countries, meaning that the trend will continue to worsen as the population ages. Hypertension rates in Asia remain the lowest in the world, but these low rates are now concentrated in eastern and southeastern Asia.
Resistant hypertension, the more severe form of hypertension that cannot be controlled with hypertension medication, is strongly affecting the South Pacific and Middle East regions. Rates of resistant hypertension are strongly influenced by obesity and diabetes, as a result, the skyrocketing prevalence of these comorbid conditions in these regions has led to nearly 20% of the hypertension population living with an underlying resistance to antihypertensive medications. Manufacturers developing neurostimulation or renal denervation technologies that address resistant hypertension are likely to see increasing demand as this prevalence rises, as projected in the Hypertension and Resistant Hypertension Global Data Report.
Pharmaceutical and Medical Device manufacturers developing hypertension therapies include Actelion, Arena Pharmaceuticals, Aires Pharmaceuticals, AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, CardioSonic, Daiichi SankyoCo., Dong-AST, Ltd., Eli Lilly, Forest Laboratories, Gilead Sciences, GlaxoSmithKline, Kona Medical, Medtronic, Mercator Medsystems, Merck , Merck Sharp & Dohme Corp, Novartis, Pfizer, Reata Pharmaceuticals, Sanofi, St. Jude Medical, Takeda Pharmaceutical, United Therapeutics, Valeant Pharmaceuticals International, and XOMA, among others.
For additional details or to obtain a copy of this new study, visit here or contact LSI.
714 847 3540
About Life Science Intelligence
Life Science Intelligence (LSI) delivers high-quality global market intelligence products to medical technology executives, entrepreneurs, and investors. LSI provides custom research services, publishes global market reports, tracks emerging medtech companies, and hosts the annual Emerging Medical Technologies Summit.
About Dymedex Consulting
Dymedex is the leading market development consulting firm advising the medical technology industry. Data-driven critical thinking, informed by broad experience and proprietary models, helps us consistently deliver critical insights. To learn more, please visit us at www.dymedex.com.
Source: PR Newswire Health
Ad Right Top
June 2015 Focus: Top 100 Biotech & DTC